The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft-Reference-Cited by-同舟云学术

The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft

Published:2021-04-28 Issue:9 Volume:56 Page:2152-2159
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Rees Matthew J.^ORCID,Mollee Peter,Ng Jun Yen,Murton Alex,Gonsalves Jose Filipe,Panigrahi Ashish,Beer Hayley,Loh Joanna,Nguyen Philip,Hunt Sam,Jina Hayden,Wayte Rebecca,Sutrave Gaurav,Tan Jocelyn,Abeyakoon Chathuri,Chee Ashlyn,Augustson Bradley,Kalro Akash,Lee Cindy,Agrawal Shivam,Churilov Leonid,Chua Chong Chyn,Lim Andrew Boon Ming,Zantomio Daniela,Grigg Andrew

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-021-01300-2.pdf

Reference45 articles.

1. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23:9227–33.

2. Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895–905.

3. Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16:1617–29.

4. Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transpl. 2009;43:619–25.

5. Varmavuo V, Mantymaa P, Silvennoinen R, Nousiainen T, Kuittinen T, Jantunen E. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. Transfusion. 2013;53:1024–32.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review;Pharmaceuticals;2024-07-15

2. Peripheral blood stem cell mobilisation following bortezomib, lenalidomide and dexamethasone induction for multiple myeloma: a real‐world single‐centre experience;Internal Medicine Journal;2023-07-23

3. Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments;Annals of Hematology;2023-03-22

4. Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation;Transfusion Medicine and Hemotherapy;2023

5. The impact of G-CSF alone vs G-CSF and cyclophosphamide mobilisation on autograft immune cell content in multiple myeloma;Bone Marrow Transplantation;2022-03-28